

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The most common Grade 3 or 4 adverse event in the PALOMA-3 study evaluating the addition of palbociclib to fulvestrant for ER-positive, HER2-negative advanced breast cancer was \_\_\_\_\_.
  - Neutropenia
  - Thrombocytopenia
  - Diarrhea
- Which of the following CDK4/6 inhibitors has demonstrated significant monotherapy response rates among patients with hormone receptor-positive metastatic breast cancer?
  - Abemaciclib
  - Palbociclib
  - Ribociclib
- The Phase III ExteNET trial, which investigated neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer, reported a significant improvement in \_\_\_\_\_ on the neratinib arm.
  - Invasive disease-free survival (DFS)
  - DFS including occurrence of DCIS
  - Both a and b
- The Phase III MARIANNE study of T-DM1 with or without pertuzumab versus trastuzumab with a taxane as first-line therapy for HER2-positive metastatic breast cancer demonstrated a significant improvement in PFS with T-DM1 alone.
  - True
  - False
- Which of the following statements is true about the results of the Phase II MDV3100-11 trial of enzalutamide for patients with advanced AR-positive TNBC?
  - Enzalutamide demonstrated a CBR at 16 weeks of 39% in patients with AR-positive TNBC
  - Enzalutamide did not demonstrate any clinical benefit in patients with AR-positive TNBC
  - Enzalutamide induced Grade 3 or higher fatigue in 5% of the overall patient population
  - As in prostate cancer, enzalutamide was associated with seizures in the overall patient population
  - Both a and c
  - Both b and d
- The results of a prospective trial of the scalp hypothermia system reported the technique to be highly effective with a success rate of approximately 70% in reducing chemotherapy-induced alopecia in women with Stage I/II breast cancer receiving nonanthracycline-based neoadjuvant or adjuvant chemotherapy regimens.
  - True
  - False
- The ongoing APHINITY trial is evaluating the addition of \_\_\_\_\_ to chemotherapy/trastuzumab as adjuvant therapy for HER2-positive primary breast cancer.
  - Eribulin
  - Bevacizumab
  - Pertuzumab
- The SWOG-S0307 trial of zoledronic acid versus ibandronate versus clodronate did not result in a significant difference among the 3 arms in terms of efficacy.
  - True
  - False
- The ongoing Phase III OlympiA trial is investigating therapy with single-agent \_\_\_\_\_ versus placebo for patients with germline BRCA-mutant, high-risk HER2-negative primary breast cancer.
  - Olaparib
  - Veliparib
  - Talazoparib
  - Cediranib
- The results of the Phase III GeparSepto (GBG 69) trial evaluating neoadjuvant chemotherapy with weekly *nab* paclitaxel versus solvent-based paclitaxel, followed by anthracycline and cyclophosphamide, for patients with early-stage breast cancer yielded a statistically significant improvement in \_\_\_\_\_ with *nab* paclitaxel.
  - Pathologic complete response rate
  - Rate of neutropenia
  - Rate of anemia
  - Both a and b
  - All of the above
  - None of the above